David Siegel
Overview
Explore the profile of David Siegel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
230
Citations
8219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oshikiri H, Taguchi K, Hirose W, Taniyama Y, Kamei T, Siegel D, et al.
Mol Cell Biol
. 2024 Dec;
45(2):79-97.
PMID: 39717011
In esophageal squamous cell carcinoma, genetic activation of NRF2 increases resistance to chemotherapy and radiotherapy, which results in a significantly worse prognosis for patients. Therefore NRF2-activated cancers create an urgent...
2.
Bangolo A, Amoozgar B, Zhang L, Nagesh V, Sekhon I, Weissman S, et al.
J Clin Med
. 2024 Oct;
13(20).
PMID: 39458157
Allogeneic stem cell transplantation (allo-SCT) has seen limited use in treating multiple myeloma (MM), despite its potential to offer long-term survival or even cure through the graft-versus-myeloma effect. Its limited...
3.
Kitson R, Kitsonova D, Siegel D, Ross D, Moody C
J Med Chem
. 2024 Oct;
67(20):17946-17963.
PMID: 39361055
Geldanamycin remains a driver in the medicinal chemistry of heat shock protein 90 (Hsp90) inhibition, even half a century after its original isolation from nature. This Perspective focuses on the...
4.
Chakrabarti R, Siegel D, Biran N
Clin Lymphoma Myeloma Leuk
. 2024 Sep;
25(2):96-108.
PMID: 39261126
Multiple myeloma (MM) is a plasma cell dyscrasia characterized by production of abnormal levels of a monoclonal immunoglobulin or plasma cell deposition that leads to end organ destruction. The disease...
5.
Bahlis N, Samaras C, Reece D, Sebag M, Matous J, Berdeja J, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Sep;
24(12):852-862.
PMID: 39237427
Background: Patients with relapsed or refractory multiple myeloma (RRMM) who have exhausted lenalidomide benefits require improved therapies. The 3-cohort phase 2 MM-014 trial (NCT01946477) explored pomalidomide in early lines of...
6.
Orlikova-Boyer B, Lorant A, Gajulapalli S, Cerella C, Schnekenburger M, Lee J, et al.
Biomark Res
. 2024 May;
12(1):47.
PMID: 38704604
Background: Despite advancements in chronic myeloid leukemia (CML) therapy with tyrosine kinase inhibitors (TKIs), resistance and intolerance remain significant challenges. Leukemia stem cells (LSCs) and TKI-resistant cells rely on altered...
7.
Tai E, Chovnick G, Momin B, Townsend J, Holman D, Siegel D, et al.
J Public Health Manag Pract
. 2023 Nov;
30(2):E54-E64.
PMID: 38032233
Context: Opportunities to reduce the risk of cancer, including cervical, liver, and skin cancer, start early in life. To encourage adoption of primary prevention activities in childhood to reduce cancer...
8.
Albitar M, Zhang H, Charifa A, Ip A, Ma W, McCloskey J, et al.
Heliyon
. 2023 May;
9(5):e16261.
PMID: 37251903
Current use of liquid biopsy is based on cell-free DNA (cfDNA) and the evaluation of mutations or methylation pattern. However, expressed RNA can capture mutations, changes in expression levels due...
9.
Usmani S, Quach H, Mateos M, Landgren O, Leleu X, Siegel D, et al.
Blood Adv
. 2023 May;
7(14):3739-3748.
PMID: 37163358
CANDOR (NCT03158688) is a phase 3, randomized, open-label trial comparing carfilzomib, daratumumab, and dexamethasone (KdD) vs carfilzomib and dexamethasone (Kd) in adults with relapsed/refectory multiple myeloma (RRMM) with 1 to...
10.
Bangolo A, Fwelo P, Trivedi C, Sagireddy S, Aljanaahi H, Auda A, et al.
World J Clin Oncol
. 2023 May;
14(4):179-189.
PMID: 37124133
Background: Extramedullary multiple myeloma (MM) (EMM) is a rare and aggressive subentity of MM that can be present at diagnosis or develop anytime during the disease course. There is a...